Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1213P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in a real-life setting (CLEAR)

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Rami Nassabein

Citation

Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729

Authors

R. Nassabein1, X. Weng2, R. Alameddine1, F. Blanc-Durand1, W. Belkaid3, M. Tehfe4, M. Florescu1, B. Routy5, N. Blais1

Author affiliations

  • 1 Hematology-oncology Dept., CHUM - Centre Hospitalier de l’Université de Montréal, H2X 3E4 - Montreal/CA
  • 2 Medical Laboratory, CHUM - Centre Hospitalier de l’Université de Montréal, H2X 3E4 - Montreal/CA
  • 3 Hemato-oncology Department, Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), H2X0A9 - Montréal/CA
  • 4 Hemato-oncology Department, CHUM - Centre Hospitalier de l’Université de Montréal, H2X 3E4 - Montreal/CA
  • 5 Hemato-oncology, University of Montreal Research Center, H2X 3H8 - Montreal/CA

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1213P

Background

Liquid biopsies have been shown to be reliable as a complementary tool to demonstrate tumor relation mutations. High procedure cost and sub-optimal sensitivity have been hurdles to public funding of this technique in Canadian centers. The CLEAR trial was designed to evaluate the clinical and economic impact of early diagnosis with circulating fragments of DNA (cfDNA) EGFR testing for suspected lung cancer patients. The objectives are to demonstrate clinically relevant improved time to detection of an EGFR mutation, evaluate the impact of cfDNA diagnosis on patient investigation and time to initiate specific EGFR inhibitor therapy.

Methods

After obtaining their consent, patients were included while undergoing investigation for a radiological suspicion of stage III/IV advanced lung cancer. CfDNA were extracted from plasma and analyzed for EGFR mutation using Cobas® EGFR Mutation Test v2.

Results

The results of the first 100 patients, out of 600 planned, recruited between November 2019 and January 2021 are reported. Median age was 65 years (range: 34-95) and 52% were female. Adenocarcinoma was confirmed in 67% of cases and 75% of the cohort had stage IV disease. About 9% of patients had no adequate tissue to perform molecular analysis and 10% of patients had undergone at least 2 biopsies. The median time to results was significantly shorter by cfDNA (median time to results: 7 vs 27 days, p<0.0001). Rate of mutations detected was 9% and 11% by cfDNA and tissue biopsy respectively. Mutation detection by cfDNA is 84.6% sensitive and 100% specific. Osimertinib was initiated within 2-27 days of the cfDNA results and 0-21 days before the tissue diagnosis in 5/9 patients. Pan cranial radiotherapy was avoided in 3 out of 4 patients with brain metastases using cfDNA results and allowed one patient with Ex20 insertion to be referred rapidly to a clinical trial.

Conclusions

EGFR mutation detection by cfDNA and tissue biopsy are complementary. Early detection by cfDNA can improve time to diagnosis and accelerate appropriate therapy. Our preliminary evaluation suggests that even earlier use of cfDNA may further improve time to treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Normand Blais.

Funding

AstraZeneca is paying the analysis fees only.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.